CAS 1132747-14-8

Formule : C38H52N6O7

InChI : InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1/i9D,10D,11D,14D,15D

Code InChI : AXRYRYVKAWYZBR-CPSMPXDPSA-N

SMILES : [2H]C1=C(C(=C(C(=C1[2H])[2H])C[C@@H]([C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)[2H])[2H]

Atazanavir-d5

Produit contrôlé

CAS : 1132747-14-8

Applications Atazanavir is a novel azapeptide HIV protease inhibitor (PI). Antiviral. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Newer research has been investigating the potential anticancer effects of atazanavir
References Palella, F.J. Jr., et al.: N. Engl. J. Med., 338(13), 853 (1998), Nolan, D., et al.: Drugs, 63(23), 2555 (2003), Musial, B.L., et al.: Am. J. Health Syst. Pharm., 61, 1365 (2004), Wood, R., et al.: J. Acquir. Immune Defic. Syndr., 36, 684 (2004),

Formule : C₃₈H₄₇D₅N₆O₇

Couleur et forme : Neat

Masse moléculaire : 709.89

Ref: TR-A790052

Atazanavir-d5

CAS : 1132747-14-8

Atazanavir-d5 is an isotopically labeled variant of the antiretroviral drug Atazanavir, a non-peptidic HIV-1 protease inhibitor. It is synthesized using stable isotope labeling, specifically deuterium, which replaces five hydrogen atoms. The mechanism of action involves binding to the active site of the HIV-1 protease enzyme, a critical enzyme in the replication cycle of HIV, thereby preventing the cleavage of the viral gag-pol polyprotein precursors into the mature protein components of an infectious viral particle.

Formule : C₃₈H₅₂N₆O₇

Degré de pureté : Min. 95%

Masse moléculaire : 709.9 g/mol

Ref: 3D-HVB74714

Atazanavir-d5

CAS : 1132747-14-8

Formule : C₃₈H₄₇D₅N₆O₇

Masse moléculaire : 709.89

Ref: ST-EA-CP-IL0081